Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Kinase Enrichment

January 17, 2011 7:35 am | Product Releases | Comments

ProFACT Proteomics and its partner in research consumables, Biotech Support Group LLC, have introduced a new reagent kit called KinaSorb, for the enrichment and isolation of kinases.


Heating And Drying Oven

January 17, 2011 7:30 am | Product Releases | Comments

Thermo Fisher Scientific Inc. announced its its Heratherm ovens, available in three different models: General Protocol, Advanced Protocol, and Advanced Protocol Security.


New Study Finds Crucial Inflammatory Protein

January 17, 2011 7:18 am | News | Comments

Scientists have identified a protein that acts as a "master switch" in certain white blood cells, determining whether they promote or inhibit inflammation.


Researchers Move Toward MRSA Vaccine

January 17, 2011 7:14 am | News | Comments

Orthopedic scientists are a step closer to developing a vaccine to prevent life-threatening methicillin-resistant staphylococcus aureus infections following bone and joint surgery.


Molecular Profiles Expanding Service

January 17, 2011 6:38 am | News | Comments

Molecular Profiles announces the expansion of its service offering to include new manufacturing capabilities, enabling the company to handle larger projects for pharmaceutical clients from preformulation through to Phase IIa.


Domain and Merck Sign mGluR4 Agreement

January 17, 2011 6:32 am | News | Comments

Domain Therapeutics announced that an exclusive development and licensing agreement with Merck Serono was signed to develop metabotropic glutamate receptor 4 positive allosteric modulator drugs targeting Parkinson’s disease and other neurodegenerative diseases.


Omthera Announces Epanova Trial Results

January 17, 2011 6:20 am | News | Comments

Omthera Pharmaceuticals, Inc. announced data from its ECLIPSE trial, designed to evaluate the bioavailability of Epanova, the company’s lead compound for treating very high triglycerides, compared to Lovaza, the leading prescription Omega 3.


GSK Takes $3.4B Avandia Charge

January 17, 2011 6:02 am | News | Comments

Pharmaceutical company GlaxoSmithKline PLC said it will take a $3.4 billion charge against earnings in the fourth quarter to provide for litigation over its diabetes drug, Avandia.


New Study Backs Combination Cancer Therapy

January 17, 2011 5:32 am | News | Comments

A new study provides a rational for treating breast cancer by combining two kinds of targeted agents, one that inhibits an overactive, cancer-causing pathway in cancer cells and one that reverses changes that silence genes that normally prevent cancer.


J & J Recalling Tylenol, Sudafed

January 17, 2011 4:56 am | News | Comments

Johnson & Johnson said it is recalling nearly 47 million packages of Tylenol, Sudafed and other nonprescription drugs manufactured at a Pennsylvania facility that has already been subject to a series of massive recalls.


High Content Data Analysis

January 14, 2011 7:37 am | Product Releases | Comments

Genedata, a provider of advanced software solutions for drug discovery and life science research, has announced the ninth version of Genedata Screener, a comprehensive software system for high content data analysis.


Personal Sequencing System

January 14, 2011 7:33 am | Product Releases | Comments

Illumina, Inc. announced MiSeq, a low-cost personal sequencing system that provides individual researchers a platform with rapid turnaround time, unmatched accuracy, and radically improved ease of use.


GM Viruses Offer Hope for Brain Tumors

January 14, 2011 7:26 am | News | Comments

New research shows that oncolytic viruses, which are engineered to destroy cancer cells, might be more effective in treating deadly brain tumors if equipped with an enzyme that helps them penetrate the tumor.


Inhibiting 12-HETE May Stop Ischemic Retinopathy

January 14, 2011 7:24 am | News | Comments

The inhibition or removal of an enzyme may prevent or treat ischemic retinopathy by stalling growth of unwanted vessels in the retina. Ischemic retinopathy is characterized by uncontrolled formation of new blood vessels in the retina.


FDA Links Multaq With Liver Damage

January 14, 2011 6:53 am | by Matthew Perrone | News | Comments

Federal health officials are warning doctors and patients that a recently-launched heart drug from Sanofi-Aventis SA has been linked to liver damage in a handful of patients.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.